US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib The Pharma Letter A Phase III randomized, multi-center registration trial of ibrutinib as a monotherapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen, RAY (MCL3001). • A Phase III ... |
